The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of AA in patients with metastatic CRPC after progression on DES: Potential cost-efficient treatment paradigm.
Feras Eleyan
No relevant relationships to disclose
Marc R. Wygoda
No relevant relationships to disclose
Tamar Peretz
No relevant relationships to disclose
Amichay Meirovitz
No relevant relationships to disclose
Hovav Nechushtan
No relevant relationships to disclose
Yakir Rottenberg
No relevant relationships to disclose
Mark Temper
No relevant relationships to disclose
Salah Azzam
No relevant relationships to disclose
Igor Nemirovsky
No relevant relationships to disclose
Eli Sapir
No relevant relationships to disclose
Stephen Jay Frank
No relevant relationships to disclose